Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F3ZG
|
|||
| Former ID |
DIB000786
|
|||
| Drug Name |
RO-5458640
|
|||
| Synonyms |
Anti-TWEAK humanized monoclonal antibody (iv, cancer), Hoffmann-La Roche
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Scantibodies Laboratory; biogen Idec
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | TNF-related weak inducer of apoptosis (TWEAK) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01383733) A Study of RO5458640 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo. MAbs. 2014 January 1; 6(1): 297-308. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.